| Literature DB >> 35888000 |
Silvia Lahuerta-Martín1,2, Rocío Llamas-Ramos3, Inés Llamas-Ramos3,4.
Abstract
Parkinson's disease (PD) is a neurodegenerative disease that alters gait patterns from early stages. The visuo-motor training strategies such as action observation (AO) and motor imagery (MI) that are based on the activity of the mirror neuron system (MNS) facilitate motor re-learning. The main purpose of this systematic review was to analyze the current scientific evidence about the effectiveness of MNS's treatments (AO and MI) to treat gait in patients with PD. Searches were completed from the databases PubMed, Web of Science, and PEDro between November and December 2021. The following keywords were used: "Parkinson disease", "mirror neurons", "gait", "action observation", and "motor imagery". Randomized control trials of the last 5 years written in English or Spanish were included. Two independent reviewers screened the articles and applied the eligibility criteria, and a third reviewer assisted in this process. A total of six articles were included for final revision. The risk of bias was assessed with the PEDro Scale. The effects of AO and MI using different outcome measures were referenced in terms of disease severity, quality of life, balance, and gait. Training with AO and MI are effective in improving disease severity, quality of life, balance, and gait in patients with PD.Entities:
Keywords: Parkinson’s disease; action observation; gait; mirror neurons; motor imagery
Year: 2022 PMID: 35888000 PMCID: PMC9321730 DOI: 10.3390/jcm11144236
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1PRISMA flowchart.
Socio-demographic and clinical variables (baseline).
| Agosta et al. [ | Abraham et al. [ | Mezzarobba et al. [ | Pelosin et al. [ | Mezzarobba et al. [ | Sarasso et al. [ | ||
|---|---|---|---|---|---|---|---|
| Sample size | EG | 12 | 10 | 12 | 33 | 12 | 13 |
| CG | 13 | 10 | 10 | 31 | 10 | 12 | |
| Age | EG | 69.0 ± 8.0 | 66.4 ± 12.5 | 74.67 ± 5.93 | 70.4 ± 4.5 | 74.67± 5.93 | 67.51 ± 6.12 |
| CG | 64.0 ± 7.0 | 65.1 ± 7.5 | 72 ± 5.87 | 72.8 ± 3.1 | 72 ± 5.87 | 63.81 ± 9.23 | |
| Gender | EG | 10 M/2 W | 9 M/1 W | 7 M/5 W | 16 M/17 W | 7 M/5 W | 8 M/5 W |
| CG | 8 M/5 W | 7 M/3 W | 7 M/3 W | 15 M/16 W | 7 M/3 W | 8 M/4 W | |
| Treatment type | AO | DNI | AO + Sonification | AO | AO + Sonification | Dual task + AO − MI | |
| Years of illness | EG | ≥5 | 6.1 ± 3.8 | 10.75 ± 3.44 | 10.7 ± 3.9 | 10.75 ± 3.44 | 8.08 ± 4.13 |
| CG | ≥5 | 8.5 ± 4.5 | 9.4 ± 4.86 | 9.5 ± 4.2 | 9.4 ± 4.86 | 7.92 ± 3.53 | |
| LEDD (mg) | EG | 897 ± 508 | NA | 972.5 ± 253.17 | 435.2 ± 158.5 | 972.5 ± 253.17 | 757.23 ± 480.49 |
| CG | 988 ± 345 | NA | 983.22 ± 379.58 | 383.1 ± 270.2 | 983.22 ± 379.58 | 555 ± 217.25 | |
| FOG | YES | YES | YES | YES | YES | YES | |
| UPDRS III | EG | 27.6 ± 9.7 | 38.4 ± 13.8 | 32.92 ± 8.69 | 31.6 ± 6.1 | 32.92 ± 8.69 | 26.27 ± 9.88 |
| CG | 23.5 ± 7.9 | 32.1 ± 12.2 | 33.2 ± 13.99 | 30.9 ± 7.2 | 33.2 ± 13.99 | 28.83 ± 8.47 | |
| Hoehn and Yahr Scale (mean ± SD) | EG | 2.3 ± 0.4 | 2.0 (1.8, 2.5) * | 2.33 ± 0.49 | 2.4 ± 0.5 | 2.33 ± 0.49 | 2.3 |
| CG | 2.2 ± 0.3 | 2.0 (2.0, 2.5) * | 2.3 ± 0.67 | 2.6 ± 0.3 | 2.3 ± 0.67 | 2.4 | |
| PDQ-39 | EG | 24.7 ± 11.1 | NA | 51.67 ± 26.9 | NA | 51.67 ± 26.9 | 18.19 ± 7.52 |
| CG | 20.2 ± 11.6 | NA | 50.8 ± 29.43 | NA | 50.8 ± 29.43 | 18.95 ± 12.16 |
Clinical variables measured before the start of treatment and ON status. * Median (first and third quartiles). EG: experimental group. CG: control group. M: men. W: women. AO: action observation. DNI: dynamic neuro-cognitive imagery. MI: motor imagery. LEDD: levodopa equivalent daily dose. Mg: milligrams. FOG: freezing of gait. UPDRS III: Unified Parkinson’s Disease Rating Scale III. SD: standard deviation. PDQ-39: 39-item Parkinson’s Disease Questionnaire. NA: not available.
Study characteristics.
| Study | Sample and Treatment | Duration | Measurements | Results |
|---|---|---|---|---|
| Agosta et al. [ | N = 25 | 60 min/day. | PRE, POST, and 4 weeks follow-up. | |
| Abraham et al. [ | N = 20 | 2 h/day. | PRE and 2–5 days POST intervention. | EG vs. CG: POST. |
| Mezzarobba et al. [ | N = 22 | 60 min/day. | PRE, POST, and 1- and 3-month follow-ups. | |
| Pelosin et al. [ | N = 64. Group intervention. | 45 min/day. | PRE, POST, and 4 weeks follow-up after treatment ends. | |
| Mezzarobba et al. [ | N = 22 | 60 min/day. | PRE, POST, and 1- and 3-months follow-ups. | |
| Sarasso et al. [ | N = 25 | 60 min/day. | PRE, POST, and 8 weeks follow-up. |
HY: Hoehn and Yahr scale. UPDRS: Unified Parkinson’s Disease Rating Scale. MDS-UPDRS: Movement Disorders Society Unified Parkinson’s Disease Rating Scale. FOG-Q: Freezing of Gait Questionnaire. NFOG- Q: New Freezing of Gait Questionnaire. 10 MWT: 10 Meters Walking Test. BBS: Berg Balance Scale. PDQ-39: Parkinson’s Disease Questionnaire—39 items. Min: minute. DNI: dynamic neurocognitive imagery. ABC: Activities Specific Balance Confidence Scale. IPA: Impact on Participation and Autonomy Scale Questionnaire. BPI: Brief Pain Inventory. BDI-II: Beck Depression Inventory-II. TUG: time up and go test. Fwd gait: forward gait speed. 6 MWT: 6 Minutes Walking Test. PRT: Push and Release Test. BSM: Brooks Spatial Memory Task. BPST: Body Position Spatial Task. MIQ-RS: Movement Imagery Questionnaire—Revised Second Version. KVIQ-20: Kinesthetic and Visual Imagery Questionnaire—20 items. VMIQ-2: Vividness of Movement Imagery Questionnaire—Revised Version. PRE: pre-treatment. POST: post-treatment. MPAS: Modified Parkinson’s Activity Scale. Mini-BESTest: Mini Balance Evaluation Systems Test. TUG-COG: time up and go + cognitive. TUG-MAN: time up and go + manual. DTC: dual task cost. AST: attention switching task.
Risk of bias: PEDro Scale.
| Agosta et al. [ | Abraham et al. [ | Mezzarobba et al. [ | Pelosin et al. [ | Mezzarobba et al. [ | Sarasso et al. [ | |
|---|---|---|---|---|---|---|
| Eligibility criteria | Yes | Yes | Yes | Yes | No | Yes |
| Random participant allocation | Yes | Yes | Yes | Yes | Yes | Yes |
| Concealed allocation | Yes | No | Yes | No | No | Yes |
| Groups similar at baseline | Yes | Yes | Yes | Yes | No | Yes |
| Subjects blinding | No | No | No | No | No | No |
| Therapist blinding | No | No | No | No | No | No |
| Assessor blinding | Yes | No | Yes | No | No | Yes |
| Less than 15% dropouts | No | No | Yes | Yes | No | Yes |
| Intention to treat analysis | No | No | Yes | No | No | No |
| Between groups statistical comparisons | Yes | Yes | Yes | Yes | Yes | Yes |
| Point measures and variability data | Yes | Yes | Yes | Yes | Yes | Yes |
| Total | 6/10 | 4/10 | 8/10 | 5/10 | 3/10 | 7/10 |